Sanofi Vaccine Messaging Commitments Become Binding
Older adults in Germany and France will see flu vaccine promotions that reference national recommendations through March 2030.
Updated on Nov. 4, 2026 in COVID-19

The European Commission has made legally binding commitments from Sanofi that address alleged disparagement of Fluad, a competing influenza vaccine for older adults. The commitments cover communications in Germany and France and run until March 2030, affecting how the drugmaker promotes its Efluelda vaccine to healthcare professionals and key opinion leaders.
Why it matters
Vaccine recommendations for older adults shape which influenza products clinicians consider and recommend, so promotional messaging to healthcare professionals can influence real prescribing choices. The Commission's preliminary concern was that certain communications may have restricted competition between the two vaccines.
The Commission ran a market test between July and August 2026 on Sanofi's initial proposal, then revised it to extend proactive communication commitments to key opinion leaders in Germany. The Commission's concerns are preliminary and rest on alleged communications directed at healthcare professionals, not on a completed adjudication.
The players
European Commission
The European Union's executive body, which enforces competition law under Article 102 of the Treaty on the Functioning of the European Union and oversees public health policy coordination across member states.
Sanofi
A global pharmaceutical company with a major vaccines business, whose influenza portfolio includes Fluad and Efluelda for older adults.
The details
Sanofi has committed to refrain from promotional statements in Germany and France that criticize national vaccination recommendations or portray Fluad negatively. It will include references to national vaccination recommendations in most Efluelda promotional materials in Germany and publish a clarifying statement on German and French websites for 24 months, stating that national recommendations consider Fluad and Efluelda equivalent in protecting elderly people against influenza. A monitoring trustee will oversee implementation and report regularly to the Commission.
Timeline
Alleged disparagement campaigns occurred between 2024 and autumn 2025.
A market test on Sanofi's proposal was conducted from July to August 2026.
Sanofi's commitments expire in March 2030.
Health Landscape
The case applies Article 102 of the Treaty on the Functioning of the European Union, the bloc's prohibition on abuse of dominant market position, to promotional messaging about influenza vaccines for older adults. It shows competition enforcement reaching into how vaccines are described to clinicians, a channel that shapes which products receive national recommendations and uptake.
Older adults and their caregivers may see differing vaccine messaging in Germany and France, so asking a clinician which influenza vaccine suits an individual's situation is worthwhile. The clarifying statement says national recommendations treat Fluad and Efluelda as equivalent in protecting elderly people against influenza.
The takeaway
Both Fluad and Efluelda are described by national recommendations as equivalent in protecting older adults against influenza, a point the clarifying statement will repeat. Older adults can raise seasonal flu vaccine options with their physician, who can explain which product fits their circumstances.
What happens next
Sanofi's commitments remain in force until March 2030, and the monitoring trustee will report regularly to the Commission during that period.
Further reading
For broader context on vaccine policy and public health, explore our COVID-19 coverage.


